Health Canada approved the first generic version of Novo Nordisk’s GLP‑1 diabetes drug Ozempic on April 29, 2026, marking the first time a G7 country has cleared a generic for the Danish company’s flagship therapy. The approval was granted to Indian manufacturer Dr Reddy’s Laboratories, which had filed its abbreviated new drug submission in January 2024 and has been awaiting regulatory review for more than two years.
The decision is significant because Canada’s patent protection for Ozempic expired in January 2026, opening the door for generic competition. In Canada, generics can be priced 45 % to 90 % lower than brand‑name drugs; the first generic is expected to be priced at roughly 75 % to 85 % of the brand price, with further price reductions anticipated as additional generics enter the market. This pricing advantage threatens Novo Nordisk’s ability to maintain its premium pricing and could erode its revenue and margin contribution from Ozempic in Canada.
Novo Nordisk’s guidance for 2026 reflects the headwinds from generic entry. The company now projects adjusted sales growth of –5 % to –13 % at constant exchange rates, a downgrade from prior expectations. The loss of pricing power in Canada is a key driver of this outlook, as Ozempic sales have been a substantial portion of the company’s obesity and diabetes portfolio. The company’s Q1 2026 earnings, scheduled for May 6, will likely provide further detail on the financial impact of the generic approval.
Health Canada is reviewing eight other generic GLP‑1 submissions, indicating a crowded pipeline and the potential for additional price erosion in the coming months. The approval of Dr Reddy’s generic is the first of several that could intensify competition for Novo Nordisk’s GLP‑1 products, including Wegovy, and may accelerate the decline in market share and pricing power in Canada and potentially in other markets where patents have expired.
The market reacted to the announcement with a 3 % decline in Novo Nordisk’s American depositary shares midday on Wednesday, reflecting investor concern that the generic approval will reduce the company’s Canadian revenue and margin contribution. The drop underscores the perceived severity of the competitive threat posed by the generic entry.
Looking ahead, Novo Nordisk will need to navigate the pricing pressure in Canada while maintaining its global growth strategy. The company’s guidance signals caution, and the upcoming Q1 earnings will likely detail the immediate financial impact of the generic approval. Investors will be watching for how Novo Nordisk adjusts its pricing strategy and whether it can mitigate the erosion of its Canadian market share through product innovation or market expansion elsewhere.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.